Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
5
×
national blog main
national top stories
roche
5
×
biotech
boston blog main
boston top stories
fda
national
new york blog main
new york top stories
san francisco blog main
san francisco top stories
boston
boulder/denver blog main
boulder/denver top stories
cancer
clinical trials
companion diagnostic
deals
detroit blog main
detroit top stories
drug pricing
europe top stories
foundation medicine
genentech
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
advaxis
aimmune therapeutics
alder biopharmaceuticals
alexander hardy
What
medicine
5
×
fda
roche
approved
big
billion
drug
new
recently
second
therapy
acquire
agreed
approval
atrophy
betting
bio
biopharma
bosley's
bosley’s
bridge
broad
bucks
cancer
cas
ceo
confidence
crime
crispr
daily
deal
deeper
departure
didn’t
dna
duchenne
editas
evrysdi
exit
fingerprint
Language
unset
Current search:
roche
×
medicine
×
" life sciences "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine